Bridgebio
Founded 2014 · 1,034 employees on LinkedIn · 7 known investors
BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Investors · 7
Frequently asked questions
- What does Bridgebio do?
- BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
- Who are Bridgebio's investors?
- Bridgebio's investors include Aisling Capital, Amzak Health, EcoR1 Capital, Frazier Life Sciences, HEALTHCARE ROYALTY PARTNERS, Longwood Fund, Sequoia Capital.